Suzuki T, et al. - In postmenopausal osteoporosis (OP) patients with rheumatoid arthritis (RA), researchers compared the outcomes of bisphosphonate-pretreated denosumab therapy with or without vitamin D and calcium supplementation. They also assessed bone mineral density (BMD) of the lumbar 1–4 vertebrae (L-BMD) and bilateral total hips (H-BMD) at the same time points. For this 3-year retrospective study, 58 patients under long-term denosumab treatment were divided into groups without (denosumab group; 31 cases) or with (combination group; 27 cases) vitamin D and calcium supplementation. No significant differences were found in the percent changes of serum albumin-corrected calcium between the groups. The combination group displayed significantly increased serum zinc, L-BMD, and H-BMD at 3 years in OP patients with RA compared to denosumab monotherapy. Calcium and vitamin D supplementation may, therefore, be beneficial to enhance BMD gains, but not necessarily 25-hydroxyvitamin D status, in patients with denosumab OP and RA.